Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.
Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.
Sells prescription drugs in Japan through its own sales reps, with a mature urology treatment, silodosin, also licensed to overseas partners that pay royalties. It also in-licenses drugs for Japan from other companies rather than relying only on its own research.
In one line: A small/mid Japanese pharma, like a smaller Ono Pharmaceutical.
Moat: narrow (IP / patents). Patent-protected niche drugs, but a smaller pipeline than major domestic pharma peers.
Headquarters: Matsumoto, Japan · Founded: 1946 · Employees: 1,786
Size Kissei Pharmaceutical (4547.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.14B, the 684th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,455 on 18 Nov 2026.
Performance Over six months the shares gained 3.5%, against -11.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 5.9% over the last twelve months (peer median -0.9%); the operating margin is 5.8% (peer median -4.9%).
Valuation It trades at 14.5× forward earnings against a peer median of 20.2× (3rd cheapest of 11).
Capital Return on invested capital runs 2.8 points below its cost of capital (5.0% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥97.1B | ¥97.4B | ¥88.3B | ¥75.6B | ¥67.5B |
| Revenue growth | — | +10% | +17% | +12% | — |
| Gross profit | ¥44.8B | ¥43.0B | ¥41.0B | ¥34.4B | ¥29.7B |
| EBITDA | ¥10.4B | ¥1.72B | ¥10.6B | ¥8.27B | ¥2.97B |
| Net income | ¥11.2B | ¥13.8B | ¥12.0B | ¥11.2B | ¥10.5B |
| Free cash flow | n/a | -¥6.37B | ¥2.01B | -¥2.88B | -¥8.78B |
| Capital expenditure | n/a | ¥5.64B | ¥8.56B | ¥3.09B | ¥7.24B |
| Total debt | ¥1.70B | ¥1.48B | ¥1.60B | ¥1.73B | ¥1.95B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kissei Pharmaceutical 4547.T | $1.14B | +3% | +6% | 6% | 14.5× | n/a |
| ONO Pharmaceutical 4528.T | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% |
| Nippon Shinyaku 4516.T | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4547.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.7% | -2.0% | 2nd highest of 21 |
| 6-month return | +3.5% | -11.7% | 6th highest of 20 |
| Distance from 52-week high | -11.6% | -35.1% | 3rd highest of 21 |
| Revenue growth (TTM) | +5.9% | -0.9% | 9th highest of 18 |
| Operating margin | 5.8% | -4.9% | 8th highest of 19 |
| Forward P/E | 14.5× | 20.2× | 3rd cheapest of 11 |
| ROIC minus cost of capital | -2.8 pp | -9.3 pp | 7th highest of 18 |
| EV / EBITDA | 12.6× | 14.1× | 2nd cheapest of 5 |
| Net debt / EBITDA | -5.0× | -0.3× | least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |